CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Lopinavir-RitonavirWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (7)

Name (Synonyms) Correlation
drug2255 Sildenafil citrate tablets Wiki 0.71
drug2194 Sampling of tissue Wiki 0.71
drug670 Corticosteroid Wiki 0.50
drug658 Convalescent plasma Wiki 0.18
drug1086 Hydroxychloroquine Wiki 0.14
drug2527 Tocilizumab Wiki 0.13
drug262 Azithromycin Wiki 0.12

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Randomised Evaluation of COVID-19 Therapy

RECOVERY is a randomised trial investigating whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Convalescent plasma or Tocilizumab prevents death in patients with COVID-19.

NCT04381936 Severe Acute Respiratory Synd Severe Acute Respiratory Syndrome Drug: Lopinavir-Ritonavir Drug: Corticosteroid Drug: Hydroxychloroquine Drug: Azithromycin Biological: Convalescent plasma Drug: Tocilizumab
MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections

Primary Outcomes

Description: For each pairwise comparison with the 'no additional treatment' arm, the primary objective is to provide reliable estimates of the effect of study treatments on all-cause mortality.

Measure: All-cause mortality

Time: Within 28 days after randomisation

Secondary Outcomes

Description: To assess the effects of study treatment on number of days stay in hospital

Measure: Duration of hospital stay

Time: Within 28 days and up to 6 months after the main randomisation

Description: Among patients not on mechanical ventilation at baseline, the number of patients with a composite endpoint of death or need for mechanical ventilation or ECMO.

Measure: Composite endpoint of death or need for mechanical ventilation or ECMO

Time: Within 28 days and up to 6 months after the main randomisation

Other Outcomes

Description: To assess the effects of study treatment on number of patients who needed ventilation and the number of days it was required

Measure: Need for (and duration of) ventilation

Time: Within 28 days and up to 6 months after the main randomisation

Description: To assess the effects of study treatment on number of patients who needed renal replacement therapy

Measure: Need for renal replacement

Time: Within 28 days and up to 6 months after the main randomisation

Description: To assess the effects of study treatment on number of patients who develop new major cardiac arrythmias

Measure: Development of new major cardiac arrythmias

Time: Within 28 days and up to 6 months after the main randomisation

2 Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19

The aim of this study is to reduce COVID-19 related pulmonary complications in adult patients undergoing all types of elective or emergency surgery in a COVID-19 exposed environment. A Trial in Low and Middle Income Countries (LMICs) and A Trial in High Income Countries (HICs)

NCT04386070 Pulmonary Complications in Surgical Patients COVID Severe Acute Respiratory Syndrome Drug: Lopinavir-Ritonavir Drug: Hydroxychloroquine
MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections

Primary Outcomes

Description: The primary outcome is any one of the following COVID-19 specific, inpatient, postoperative pulmonary complications: Pneumonia Acute respiratory distress syndrome (ARDS) Death

Measure: Pneumonia free survival; acute respiratory distress syndrome (ARDS) free survival; or death

Time: From randomisation until discharge from hospital, average less than 30 days

Secondary Outcomes

Description: Pneumonia will be presented and analysed separately as a secondary outcome measure as well as within the composite primary outcome measure.

Measure: Rate of Pneumonia

Time: From randomisation until discharge from hospital, average less than 30 days

Description: ARDs will be presented and analysed separately as a secondary outcome measure

Measure: Rate of ARDs

Time: From randomisation until discharge from hospital, average less than 30 days

Description: Death will be presented and analysed separately as a secondary outcome measure

Measure: Death rate

Time: From randomisation until discharge from hospital, average less than 30 days

Description: Unexpected inability to extubate and wean patient from ventilation after general anaesthesia, or reintubation and ventilation by 30 days after surgery

Measure: Rate of unexpected ventilation

Time: From operation until 30 days post operation

Description: Postoperative diagnosis of proven COVID-19 pulmonary complications

Measure: COVID-19 pulmonary complications

Time: 30 days post-surgery

Description: Overall SARS-CoV-2 infected rate (symptomatic and/or asymptomatic)

Measure: Overall SARS-CoV-2 infected rate

Time: 30 days post-surgery

Description: Duration of hospital stay (including time spent in intensive care, time ventilated)

Measure: Duration of hospital stay

Time: 30 days post-surgery

Description: Pulmonary function in keeping with the World Health Organisation (WHO) Solidarity Trial outcome scale

Measure: Pulmonary function

Time: 30 days post-surgery

No related HPO nodes (Using clinical trials)